- Home
- OCGN vs TNXP Comparison
OCGN vs TNXP Comparison
Compare OCGN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- TNXP
- Stock Information
- Founded
- OCGN 2013
- TNXP 2007
- Country
- OCGN United States
- TNXP United States
- Employees
- OCGN N/A
- TNXP N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- TNXP Health Care
- Exchange
- OCGN Nasdaq
- TNXP Nasdaq
- Market Cap
- OCGN 283.3M
- TNXP 272.0M
- IPO Year
- OCGN N/A
- TNXP N/A
- Fundamental
- Price
- OCGN $1.09
- TNXP $49.73
- Analyst Decision
- OCGN Strong Buy
- TNXP Strong Buy
- Analyst Count
- OCGN 3
- TNXP 2
- Target Price
- OCGN $6.00
- TNXP $585.00
- AVG Volume (30 Days)
- OCGN 6.6M
- TNXP 1.2M
- Earning Date
- OCGN 08-01-2025
- TNXP 08-15-2025
- Dividend Yield
- OCGN N/A
- TNXP N/A
- EPS Growth
- OCGN N/A
- TNXP N/A
- EPS
- OCGN N/A
- TNXP N/A
- Revenue
- OCGN $4,522,000.00
- TNXP $10,041,000.00
- Revenue This Year
- OCGN N/A
- TNXP $22.87
- Revenue Next Year
- OCGN N/A
- TNXP $711.66
- P/E Ratio
- OCGN N/A
- TNXP N/A
- Revenue Growth
- OCGN N/A
- TNXP N/A
- 52 Week Low
- OCGN $0.52
- TNXP $6.76
- 52 Week High
- OCGN $1.67
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- OCGN 54.73
- TNXP 70.46
- Support Level
- OCGN $0.99
- TNXP $41.64
- Resistance Level
- OCGN $1.18
- TNXP $46.00
- Average True Range (ATR)
- OCGN 0.08
- TNXP 3.70
- MACD
- OCGN 0.00
- TNXP 0.38
- Stochastic Oscillator
- OCGN 54.55
- TNXP 95.84
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.